Top Markets
#1 Black Phoenix Black Phoenix +199.70%
#2 Islamic Coin Islamic Coin +158.01%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +54.36%
#5 BasedHype BasedHype +32.50%
#6 Akedo Akedo +26.93%
#7 Acurast Acurast +24.11%
#8 Cryptopia Cryptopia +21.67%
#9 Quantum Resistant Ledger Quantum Resistant Ledger +18.56%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Rang in Aktien #41698
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2025-11-07
Marktkapitalisierung
$12.63K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel InNexus Biotechnology, Inc. (IXSBF)

Kategorie

Healthcare
Anzahl der ausstehenden Aktien von InNexus Biotechnology, Inc. (IXSBF)
Anzahl der ausstehenden Aktien zum August 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von InNexus Biotechnology, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von August 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von InNexus Biotechnology, Inc. (IXSBF) von 2026 bis 2026
Ausstehende Aktien am Ende jedes Jahres
Jahr Ausstehende Aktien ändert
Nicht genügend Daten für die angegebenen Daten.
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
Unternehmen Ausstehende Aktien Unterschied Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 445.06M -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 105.38M -
US